Vlad Coric (Photo Credit: Andrew Venditti)

Bio­haven scores CGRP OK for acute mi­graine — can the com­mer­cial team catch up with Al­ler­gan on its de­but?

Sev­en years af­ter spin­ning out of Yale, Bio­haven has en­tered the ranks of com­mer­cial-stage biotechs.

The FDA hand­ed down an OK for its CGRP drug, rimegepant, as an acute treat­ment. Dubbed Nurtec, the oral­ly dis­solv­ing pill will join Al­ler­gan’s (soon to be Ab­b­Vie’s) Ubrelvy and Lil­ly’s Reyvow on the mar­ket amid a new wave of mi­graine ther­a­pies re­shap­ing the dis­ease space.

In a piv­otal Phase III tri­al, Nurtec hit the co-pri­ma­ry end­points on pain free­dom and free­dom from most both­er­some symp­toms at two hours post dose, prov­ing su­pe­ri­or to place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.